|
1
|
Li N, Zheng H, Zheng B, Chen C, Cai H and
Liu M: Economic Evaluations of Immune Checkpoint Inhibitors for
Patients with Non-Small Cell Lung Cancer: A Systematic Review.
Cancer Manag Res. 12:4503–4518. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Duma N, Santana-Davila R and Molina JR:
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and
Treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dela Cruz CS, Tanoue LT and Matthay RA:
Lung cancer: Epidemiology, etiology, and prevention. Clin Chest
Med. 32:605–644. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ghouri YA, Mian I and Rowe JH: Review of
hepatocellular carcinoma: Epidemiology, etiology, and
carcinogenesis. J Carcinog. 16:1–25. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Meyers RL, Tiao G, de Ville de Goyet J,
Superina R and Aronson DC: Hepatoblastoma state of the art:
Pre-treatment extent of disease, surgical resection guidelines and
the role of liver transplantation. Curr Opin Pediatr. 26:29–36.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kabaria R, Klaassen Z and Terris MK: Renal
cell carcinoma: Links and risks. Int J Nephrol Renovasc Dis.
9:45–52. 2016.PubMed/NCBI
|
|
7
|
Tsai FJ, Liu X, Chen CJ, Li TM, Chiou JS,
Chuang PH, Ko CH, Lin TH, Liao CC, Huang SM, et al: Chinese herbal
medicine therapy and the risk of overall mortality for patients
with liver cancer who underwent surgical resection in Taiwan.
Complement Ther Med. 47:1022132019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu Z, Suo C, Mao X, Jiang Y, Jin L, Zhang
T and Chen X: Global incidence trends in primary liver cancer by
age at diagnosis, sex, region, and etiology, 1990–2017. Cancer.
126:2267–2278. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Roseweir AK, Qayyum T, Lim Z, Hammond R,
MacDonald AI, Fraser S, Oades GM, Aitchison M, Jones RJ and Edwards
J: Nuclear expression of Lyn, a Src family kinase member, is
associated with poor prognosis in renal cancer patients. BMC
Cancer. 16:229–238. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yuan ZX, Mo J, Zhao G, Shu G, Fu HL and
Zhao W: Targeting strategies for renal cell carcinoma: From renal
cancer cells to renal cancer stem cells. Front Pharmacol.
7:423–438. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kamal A, Khan MN, Srinivasa Reddy K and
Rohini K: Synthesis of a new class of 2-anilino substituted
nicotinyl arylsulfonylhydrazides as potential anticancer and
antibacterial agents. Bioorg Med Chem. 15:1004–1013. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
El-Kerdawy MM, Ghaly MA, Darwish SA,
Abdel-Aziz HA, Elsheakh AR, Abdelrahman RS and Hassan GS: New
benzimidazothiazole derivatives as anti-inflammatory, antitumor
active agents: Synthesis, in-vitro and in-vivo screening and
molecular modeling studies. Bioorg Chem. 83:250–261. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Siemann S, Evanoff DP, Marrone L, Clarke
AJ, Viswanatha T and Dmitrienko GI: N-arylsulfonyl
hydrazones as inhibitors of IMP-1 metallo-β-lactamase. Antimicrob
Agents Chemother. 46:2450–2457. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Backes GL, Neumann DM and Jursic BS:
Synthesis and antifungal activity of substituted salicylaldehyde
hydrazones, hydrazides and sulfohydrazides. Bioorg Med Chem.
22:4629–4636. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Neumann DM, Cammarata A, Backes G, Palmer
GE and Jursic BS: Synthesis and antifungal activity of substituted
2,4,6-pyrimidinetrione carbaldehyde hydrazones. Bioorg Med Chem.
22:813–826. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Naeem S, Akhtar S, Asghar N, Sherwani SK,
Mushtaq N, Kamil A, Zafar S, Arif M and Saify ZS: Antimicrobial and
antioxidant screening of N′-substituted sulphonyl and benzoyl
derivatives of 4-Pyridine carboxylic acid hydrazide. Pak J Pharm
Sci. 28:2129–2134. 2015.PubMed/NCBI
|
|
17
|
Bhat M, Poojary B, Kumar SM, Hussain MM,
Pai N, Revanasiddappa BC and Byrappa K: Structural,
crystallographic, Hirshfeld surface, thermal and antimicrobial
evaluation of new sulfonyl hydrazones. J Mol Struct. 1159:55–66.
2018. View Article : Google Scholar
|
|
18
|
Sondhi SM, Dinodia M and Kumar A:
Synthesis, anti-inflammatory and analgesic activity evaluation of
some amidine and hydrazone derivatives. Bioorg Med Chem.
14:4657–4663. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Popiołek Ł: Hydrazide-hydrazones as
potential antimicrobial agents: Overview of the literature since
2010. Med Chem Res. 26:287–301. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Popiołek Ł and Biernasiuk A: Design,
synthesis, and in vitro antimicrobial activity of
hydrazide-hydrazones of 2-substituted acetic acid. Chem Biol Drug
Des. 88:873–883. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Popiołek Ł and Biernasiuk A:
Hydrazide-hydrazones of 3-methoxybenzoic acid and
4-tert-butylbenzoic acid with promising antibacterial
activity against Bacillus spp. J Enzyme Inhib Med Chem.
31((S1)): 62–69. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Popiołek Ł and Biernasiuk A: Synthesis and
investigation of antimicrobial activities of nitrofurazone
analogues containing hydrazide-hydrazone moiety. Saudi Pharm J.
25:1097–1102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Popiołek Ł, Biernasiuk A, Berecka A,
Gumieniczek A, Malm A and Wujec M: New hydrazide-hydrazones of
isonicotinic acid: Synthesis, lipophilicity and in vitro
antimicrobial screening. Chem Biol Drug Des. 91:915–923. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Popiołek Ł, Piątkowska-Chmiel I,
Gawrońska-Grzywacz M, Biernasiuk A, Izdebska M, Herbet M, Sysa M,
Malm A, Dudka J and Wujec M: New hydrazide-hydrazones and
1,3-thiazolidin-4-ones with 3-hydroxy-2-naphthoic moiety:
Synthesis, in vitro and in vivo studies. Biomed Pharmacother.
103:1337–1347. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nič M, Jirát J, Košata B, Jenkins A and
McNaught A: Compendium of Chemical Terminology. IUPAC; Research
Triagle Park, NC: 2009, https://doi.org/10.1351/goldbook
|
|
26
|
Arnott JA, Kumar R and Planey SL:
Lipophilicity indices for drug development. J App Biopharm
Pharmacokin. 1:31–36. 2013.
|
|
27
|
Lipinski CA, Lombardo F, Dominy BW and
Feeney PJ: Experimental and computational approaches to estimate
solubility and permeability in drug discovery and development
settings. Adv Drug Deliv Rev. 46:3–26. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Arnott JA and Planey SL: The influence of
lipophilicity in drug discovery and design. Expert Opin Drug
Discov. 7:863–875. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Waring MJ: Lipophilicity in drug
discovery. Expert Opin Drug Discov. 5:235–248. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Komsta Ł, Skibiński R, Berecka A,
Gumieniczek A, Radkiewicz B and Radoń M: Revisiting thin-layer
chromatography as a lipophilicity determination tool - a
comparative study on several techniques with a model solute set. J
Pharm Biomed Anal. 53:911–918. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hawrył A, Popiołek Ł, Dobosz M, Pikula E
and Waksmundzka-Hajnos M: RP-HPTLC determination of the
lipophilicity of some new derivatives of thiosemicarbazide and
1,2,4-triazole of sulphanylacetic acid. Acta Chromatogr. 22:37–55.
2010. View Article : Google Scholar
|
|
32
|
Tetko IV, Gasteiger J, Todeschini R, Mauri
A, Livingstone D, Ertl P, Palyulin VA, Radchenko EV, Zefirov NS,
Makarenko AS, et al: Virtual computational chemistry laboratory -
design and description. J Comput Aided Mol Des. 19:453–463. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
VCCLAB, . Virtual Computational Chemistry
Laboratory. http://www.vcclab.org2005
|
|
34
|
Aydın A, Korkmaz SA, Demir V and Tekin S:
Anticancer and Cytotoxic Activities of
[Cu(C6H16N2O2)2][Ni(CN)4]
and
[Cu(C6H16N2O2)Pd(CN)4]
Cyanidometallate Compounds on HT29, HeLa, C6 and Vero Cell Lines.
Anticancer Agents Med Chem. 17:865–874. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gul HI, Yamali C, Bulbuller M,
Kirmizibayrak PB, Gul M, Angeli A, Bua S and Supuran CT: Anticancer
effects of new dibenzenesulfonamides by inducing apoptosis and
autophagy pathways and their carbonic anhydrase inhibitory effects
on hCA I, hCA II, hCA IX, hCA XII isoenzymes. Bioorg Chem.
78:290–297. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Verma R, Bairy I, Tiwari M, Bhat GV and
Shenoy GG: In silico studies, synthesis and anticancer activity of
novel diphenyl ether-based pyridine derivatives. Mol Divers.
23:541–554. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
He H, Wang X, Shi L, Yin W, Yang Z, He H
and Liang Y: Synthesis, antitumor activity and mechanism of action
of novel 1,3-thiazole derivatives containing hydrazide-hydrazone
and carboxamide moiety. Bioorg Med Chem Lett. 26:3263–3270. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Abdel-Wahab BF, Awad GEA and Badria FA:
Synthesis, antimicrobial, antioxidant, anti-hemolytic and cytotoxic
evaluation of new imidazole-based heterocycles. Eur J Med Chem.
46:1505–1511. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mohamed Eissa AA, Soliman GA and Khataibeh
MH: Design, synthesis and anti-inflammatory activity of
structurally simple anthranilic acid congeners devoid of
ulcerogenic side effects. Chem Pharm Bull (Tokyo). 60:1290–1300.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
el-Sabbagh OI and Rady HM: Synthesis of
new acridines and hydrazones derived from cyclic beta-diketone for
cytotoxic and antiviral evaluation. Eur J Med Chem. 44:3680–3686.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lima LM, Frattani FS, Dos Santos JL,
Castro HC, Fraga CA, Zingali RB and Barreiro EJ: Synthesis and
anti-platelet activity of novel arylsulfonate - acylhydrazone
derivatives, designed as antithrombotic candidates. Eur J Med Chem.
43:348–356. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mashayekhi V, Haj Mohammad Ebrahim Tehrani
K, Amidi S and Kobarfard F: Synthesis of novel indole hydrazone
derivatives and evaluation of their antiplatelet aggregation
activity. Chem Pharm Bull (Tokyo). 61:144–150. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Alam MS, Choi SU and Lee DU: Synthesis,
anticancer, and docking studies of salicyl-hydrazone analogues: A
novel series of small potent tropomyosin receptor kinase A
inhibitors. Bioorg Med Chem. 25:389–396. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
El-Faham A, Farooq M, Khattab SN, Abutaha
N, Wadaan MA, Ghabbour HA and Fun HK: Synthesis, characterization,
and anti-cancer activity of some new
N′-(2-oxoindolin-3-ylidene)-2-propylpentane
hydrazide-hydrazones. Molecules. 20:14638–14655. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kodisundaram P, Duraikannu A, Balasankar
T, Sundarao Ambure P and Roy K: Cytotoxic and antioxidant activity
of a set of hetero bicylic methylthiadiazole hydrazones: A
structure-activity study. Int J Mol Cell Med. 4:128–137.
2015.PubMed/NCBI
|
|
46
|
Nikolova-Mladenova B, Momekov G, Ivanov D
and Bakalovaa A: Design and drug-like properties of new
5-methoxysalicylaldehyde based hydrazones with anti-breast cancer
activity. J Appl Biomed. 15:233–240. 2017. View Article : Google Scholar
|
|
47
|
Taha M, Shah SAA, Afifi M, Zulkeflee M,
Sultan S, Wadood A, Rahim F and Ismail NH: Morpholine hydrazone
scaffold: Synthesis, anticancer activity and docking studies. Chin
Chem Lett. 28:607–611. 2017. View Article : Google Scholar
|
|
48
|
Shang H, Li L, Ma L, Tian Y, Jia H, Zhang
T, Yu M and Zou Z: Design and Synthesis of Molecular Hybrids of
Sophora Alkaloids and Cinnamic Acids as Potential Antitumor Agents.
Molecules. 25(pii): E11682020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tang BD, Xia X, Lv XF, Yu BX, Yuan JN, Mai
XY, Shang JY, Zhou JG, Liang SJ and Pang RP: Inhibition of
Orai1-mediated Ca2+ entry enhances chemosensitivity of
HepG2 hepatocarcinoma cells to 5-fluorouracil. J Cell Mol Med.
21:904–915. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Baharuddin P, Satar N, Fakiruddin KS,
Zakaria N, Lim MN, Yusoff NM, Zakaria Z and Yahaya BH: Curcumin
improves the efficacy of cisplatin by targeting cancer stem-like
cells through p21 and cyclin D1-mediated tumour cell inhibition in
non-small cell lung cancer cell lines. Oncol Rep. 35:13–25. 2016.
View Article : Google Scholar : PubMed/NCBI
|
